Clariane SE

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0010386334
EUR
3.41
-22.15 (-86.67%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Negative results in Jun 25

  • OPERATING CASH FLOW(Y) Lowest at EUR 1,249.57 MM
  • PRE-TAX PROFIT(Q) Lowest at EUR -34.1 MM
  • INVENTORY TURNOVER RATIO(HY) Lowest at 148.8 times
2

With ROE of 3.87%, it has a Very Expensive valuation with a 0.37 Price to Book Value

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 1,249 Million ()

stock-summary
P/E

10.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.96

stock-summary
Return on Equity

3.87%

stock-summary
Price to Book

0.35

Revenue and Profits:
Net Sales:
281 Million
(Quarterly Results - Dec 2012)
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-90.2%
0%
-90.2%
6 Months
-87.89%
0%
-87.89%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Clariane SE for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
6.51%
EBIT Growth (5y)
-0.49%
EBIT to Interest (avg)
1.43
Debt to EBITDA (avg)
3.89
Net Debt to Equity (avg)
1.04
Sales to Capital Employed (avg)
0.59
Tax Ratio
25.72%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.60%
ROE (avg)
2.47%

Valuation key factors

Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
0.37
EV to EBIT
16.17
EV to EBITDA
4.74
EV to Capital Employed
0.68
EV to Sales
0.90
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
4.19%
ROE (Latest)
3.87%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Clariane SE"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.54% vs 4.64% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 134.20% vs 66.50% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,310.30",
          "val2": "5,281.80",
          "chgp": "0.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,012.20",
          "val2": "1,006.70",
          "chgp": "0.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "311.00",
          "val2": "336.40",
          "chgp": "-7.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-149.50",
          "val2": "-0.20",
          "chgp": "-74,650.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "9.20",
          "val2": "-26.90",
          "chgp": "134.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "55.90%",
          "val2": "56.80%",
          "chgp": "-0.09%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
5,310.30
5,281.80
0.54%
Operating Profit (PBDIT) excl Other Income
1,012.20
1,006.70
0.55%
Interest
311.00
336.40
-7.55%
Exceptional Items
-149.50
-0.20
-74,650.00%
Consolidate Net Profit
9.20
-26.90
134.20%
Operating Profit Margin (Excl OI)
55.90%
56.80%
-0.09%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 0.54% vs 4.64% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 134.20% vs 66.50% in Dec 2024

stock-summaryCompany CV
About Clariane SE stock-summary
stock-summary
Clariane SE
Pharmaceuticals & Biotechnology
Korian SA, formerly Korian Medica SA, is a France-based company that operates healthcare facilities and medical establishments. The Company's holdings include residential centers for the elderly, offering permanent social care and medical support; follow-up care and rehabilitation centers, including general and specialized centers. Furthermore, the Company offers hospitalization at home, which avoids or shortens the hospitalization process; and home nursing services, which allows the care prescribes by a doctor at home. Korian-Medicas' establishments are located in France, Italy and Germany via its subsidiaries, Segesta S.p.A., Phonix GmBH, Reacti Malt SAS, Sas La Normandie, Sa La Bastide de la tourne, Sas Mapadex La Roseraie, among others.
Company Coordinates stock-summary
Company Details
Cs 40070, Paris Cedex 17 , PARIS None : 75858
stock-summary
Tel: 33 1 55375200
stock-summary
Registrar Details